Stockscreener 앱 받기
108.33
0.42%
-0.46
시간 외 거래:
108.44
0.11
+0.10%
전일 마감가:
$108.79
열려 있는:
$108.105
하루 거래량:
6.88M
Relative Volume:
0.62
시가총액:
$187.45B
수익:
$46.59B
순이익/손실:
$5.41B
주가수익비율:
35.02
EPS:
3.0938
순현금흐름:
$7.38B
1주 성능:
-3.68%
1개월 성능:
+2.72%
6개월 성능:
-4.22%
1년 성능:
-18.43%
1일 변동 폭
$107.36
$110.01
1주일 범위
$107.36
$113.91
52주 변동 폭
$81.97
$137.49
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Blocks Rival's Glucose Monitor Sales In Europe - Law360
Novocure Reports Patient Data Exposure in Cybersecurity Incident - Zacks Investment Research
Abbott Laboratories stock holds valuation premium amid steady earnings - AD HOC NEWS
Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets - simplywall.st
Abbott Laboratories stock holds near $108 after strong Q2 - AD HOC NEWS
Abbott Laboratories Profile: Recipients - opensecrets.org
How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story - simplywall.st
Abbott CFO Philip P. Boudreau Retains 70,784 Shares After Forfeiting 388 Shares at $110.36 Each - Kalkine Media
Ferguson Wellman Capital Management Inc. Sells 136,385 Shares of Abbott Laboratories $ABT - InsuranceNewsNet
Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.
US companies face rise in cyber attacks - reuters.com
Abbott Laboratories CFO Philip P. Boudreau Reports Sale of 388 Shares at $110.36 in SEC Form 4 Filing - kalkinemedia.com
Abbott Laboratories VP John A. McCoy Jr. Reports Share Sales on September 1-2, 2026 - kalkinemedia.com
Abbott Laboratories (ABT) CFO reports small tax-related share disposal - Stock Titan
Abbott Laboratories stock underperforms Thursday when compared to competitors - MarketWatch
Abbott Laboratories stock gains support from fresh earnings and guidance - AD HOC NEWS
Abbott ablation device effective at 1 year in complex cases - MedTech Dive
Abbott Laboratories stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
Abbott settlement and Kendamil case add to formula industry scrutiny - FoodNavigator.com
Abbott Introduces America’s First Liquid Baby Formula With Whole Milk - Yahoo Finance
Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector? - Barchart.com
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
How Abbott Labs Is Embracing RFK Jr.'s Make America Healthy Again Movement - Investor's Business Daily
Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends - 24/7 Wall St.
Abbott Laboratories Introduces Similac 360 Total Care Made With Whole Milk in US - marketscreener.com
No mixing: Similac's whole-milk formula launches at powder-like prices - Stock Titan
Abbott Laboratories (ABT) Stock Analysis: A Healthy Outlook With A 6.87% Upside - DirectorsTalk Interviews
Abbott Laboratories (ABT) Could Be 6% Below Fair Value Following Libre Duo FDA Approval - simplywall.st
Abbott wins CE mark for new LAA closure device - medtechdive.com
Abbott Laboratories agrees to $670M settlement over premature infant formula claims - Top Class Actions
Lawsuit accusing Abbott MitraClip of kickbacks will proceed - Courthouse News
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
Analyst recommendations: Nvidia, Intuit, BofA, Abbott Laboratories, Google… - marketscreener.com
Why Is Abbott Laboratories (ABT) Launching A First Of Its Kind Diabetes Wearable? - simplywall.st
Abbott Labs Settles Investor Formula Recall Suit for $89 Million - Bloomberg Law News
FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients - Yahoo
Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson? - The Motley Fool
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Exact Sciences stock enters new chapter after Abbott acquisition - Ad-hoc-news.de
Abbott Agrees to $670 Million Settlement in Premature Infant Formula Litigation - finance.biggo.com
Analyst Raises Abbott Price Target to $135 on Strengthening Cancer Diagnostics Growth and Successful Exact Sciences Integration - TipRanks
TD Cowen raises Abbott Labs stock price target on cancer diagnostics growth - Investing.com
Abbott Laboratories settles multitude of infant formula legal claims - Yahoo Finance
Abbott Bypasses Appeals Process To Settle Ongoing Premature Infant Formula Litigation - Yahoo Finance
Abbott agreed to pay $670 million to settle preterm baby formula lawsuits - qz.com
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115 - Moomoo
Abbott Laboratories stock holds firm after Q2 beat - Ad-hoc-news.de
Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies - Times West Virginian
True North Advisors LLC Trims Stake in Abbott Laboratories $ABT - MarketBeat
Asset Advisors Investment Management LLC Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애보트 래버러토리스 주식 (ABT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Sale |
115.85 |
398,832 |
46,204,798 |
306,461 |
1.15%
1.58%
자본화:
|
볼륨(24시간):